REMS Programs: Risk Evaluation and Mitigation Strategies Explained

When a drug can save lives but also carry serious, even deadly, risks, how do you make sure it’s used safely? That’s the exact problem the U.S. Food and Drug Administration (FDA) set out to solve with REMS programs-Risk Evaluation and Mitigation Strategies. These aren’t just extra warnings on a label. They’re structured, legally required systems designed to manage the most dangerous medications on the market. Think of them as a safety net that keeps high-risk drugs available while minimizing harm. Today, 78 active REMS programs cover about 150 medications, from life-saving cancer treatments to drugs that can cause irreversible birth defects.

What Exactly Is a REMS Program?

A REMS program is a formal plan approved by the FDA to manage specific, serious risks tied to certain prescription drugs. It’s not for every medication. In fact, about 95% of approved drugs don’t need one. REMS kicks in only when the potential harm is severe enough that standard prescribing guidelines and warning labels aren’t enough. The legal foundation for REMS came from the 2007 Food and Drug Administration Amendments Act (FDAAA), which gave the FDA the power to require these programs either during a drug’s initial approval or later, if new safety data emerges.

REMS isn’t about removing risk entirely-it’s about balancing risk and benefit. For example, a drug might cause severe liver damage in 1 out of 500 patients, but it’s the only treatment that can save someone with a rare, fatal disease. The FDA doesn’t pull the drug. Instead, it builds a system around it to make sure only the right patients get it, under the right conditions.

How REMS Programs Work: The Three Main Elements

Every REMS is custom-built for the specific drug and its risks. But they all include at least one of three core elements:

• Medication Guides: These are printed handouts given to patients. They explain the risks in plain language. For example, isotretinoin (Accutane), a powerful acne drug, comes with a guide that clearly states it can cause severe birth defects if taken during pregnancy.
• Communication Plans: These are targeted messages sent to doctors, pharmacists, and sometimes hospitals. They might include training materials, emails, or alerts about new safety data. For drugs like clozapine, which can wipe out white blood cells and leave patients vulnerable to infection, these plans remind providers to order weekly blood tests during the first six months.
• Elements to Assure Safe Use (ETASU): This is the strictest layer. ETASU can require prescribers to get certified, patients to enroll in a registry, or medications to be dispensed only in certain settings. Take Zyprexa Relprevv, a long-acting shot for schizophrenia. Because it can cause sudden, life-threatening sedation after injection, it must be given in a certified clinic where staff can monitor the patient for at least three hours.

These elements aren’t optional. They’re enforced. If a pharmacy dispenses a REMS drug without verifying the prescriber’s certification or the patient’s enrollment, they’re breaking federal rules.

Why REMS Programs Exist: Real-World Examples

Some of the most famous drugs in medical history led to the creation of REMS. Thalidomide, once used to treat morning sickness in the 1950s and 60s, caused thousands of babies to be born with missing limbs. When it was revived decades later to treat leprosy and multiple myeloma, the FDA didn’t just slap on a warning. They created iPLEDGE-the most complex REMS ever built. It requires women of childbearing age to take two negative pregnancy tests, use two forms of birth control, and complete monthly counseling before getting a refill. Men must also register and avoid donating sperm.

Clozapine, used for treatment-resistant schizophrenia, can cause agranulocytosis-a dangerous drop in white blood cells. Without monitoring, it can be fatal. The REMS for clozapine requires weekly blood draws for the first six months, then every two weeks. Pharmacists must verify the lab results before filling the prescription. One hospital pharmacist told Pharmacy Times they spend up to five extra hours a week just managing clozapine checks.

Even newer drugs like the long-acting opioid Zohydro ER were put under REMS after concerns about misuse. The program requires prescribers to complete training on opioid safety and document patient risk assessments. But critics say the training doesn’t actually reduce abuse-it just adds paperwork.

Who Pays for REMS? And Who Bears the Burden?

The pharmaceutical company that makes the drug is legally responsible for designing, funding, and running the REMS program. That means they pay for training, registries, patient outreach, and technology systems. The cost varies wildly. A simple medication guide might cost $500,000 a year. A full ETASU program with patient registries, certified prescribers, and pharmacy verification systems can cost over $15 million annually.

But the real cost isn’t just financial-it’s time. A 2022 survey of 1,250 U.S. doctors found that 68% had delayed starting a REMS drug because of paperwork. For patients with rare diseases, that delay can mean worsening symptoms or hospitalization. One mother in Ohio described how her daughter’s rare epilepsy drug took 11 days to start because of REMS verification delays.

Pharmacists are hit hard too. Community pharmacies report spending 15-20 minutes per REMS prescription just to verify eligibility. In hospitals, that time adds up. One pharmacist on Reddit wrote: “I’ve had patients cry because their isotretinoin was delayed a week because the iPLEDGE portal was down.”

Is REMS Working? The Debate

Supporters say REMS has made the drug supply safer. Dr. Robert Temple, former FDA deputy director, called REMS “essential” for bringing critical therapies to patients who would otherwise have no options. He points to drugs like thalidomide and clozapine-both of which are now used safely because of REMS.

But critics argue that many REMS programs create more harm than good. Dr. Aaron Kesselheim of Harvard testified in 2021 that some REMS, like the one for extended-release opioids, added bureaucracy without reducing abuse. A 2019 study in JAMA Internal Medicine found REMS drugs took an average of 5.4 days longer to be prescribed than non-REMS drugs. For patients in rural areas or with limited mobility, that delay can be dangerous.

The FDA admits the system isn’t perfect. In 2022, former Acting Commissioner Dr. Janet Woodcock said, “Not all REMS programs have been equally effective.” Since then, the agency has started sunsetting programs. In August 2023, the FDA ended the REMS for thalidomide after 20 years-because better education and alternative controls made it unnecessary.

What’s Changing in REMS? The Future

The FDA is trying to fix the system. In 2023, they launched the REMS Integration Initiative, pushing 22 of the 78 active programs onto one shared digital platform. The goal? Cut down on the chaos of logging into 20 different systems just to prescribe one drug.

They’re also testing digital tools. Pilot programs are now using smartphone apps to monitor patients on anticoagulants, replacing in-person visits with real-time data from wearable devices. If it works, it could cut REMS delays by half.

But challenges remain. A joint FDA-PhRMA report from September 2023 found that 63% of REMS programs have no way to measure whether they actually improve safety. Without data, there’s no way to know if the delays, costs, and frustrations are worth it.

Looking ahead, Evaluate Pharma predicts that by 2027, nearly half of all new cancer drugs will need REMS. As drugs get more targeted-and more dangerous-REMS will only grow. The real question isn’t whether we need it. It’s whether we can make it smarter.